Introduction: [²²⁷Th]Th-3,2-HOPO-MSLN-mAb, a mesothelin (MSLN)-targeted thorium-227 therapeutic conjugate, is currently in phase I clinical trial; however, direct PET imaging using this conjugate is technically challenging. Thus, using the same MSLN antibody, we synthesized 3,2-HOPO and deferoxamine (DFO)-based zirconium-89 antibody conjugates, [⁸⁹Zr]Zr-3,2-HOPO-MSLN-mAb and [⁸⁹Zr]Zr-DFO-MSLN-mAb, respectively, and compared them in vitro and in vivo.

中文翻译：

---

3,2-HOPO 与基于去铁胺的锆 89 螯合与抗间皮素抗体 Anetumab 的体外和体内比较

简介： [ ²²⁷ Th] Th-3,2-HOPO-MSLN-mAb 是一种间皮素 (MSLN) 靶向钍-227 治疗偶联物，目前处于 I 期临床试验阶段；然而，使用这种结合物的直接 PET 成像在技术上具有挑战性。因此，使用相同的 MSLN 抗体，我们合成了基于 3,2-HOPO 和去铁胺 (DFO) 的锆-89 抗体偶联物、[ ⁸⁹ Zr]Zr-3,2-HOPO-MSLN-mAb 和 [ ⁸⁹ Zr]Zr- DFO-MSLN-mAb 分别进行体外和体内比较。